Infectious Diseases News and Research

RSS

NO could improve recovery of critically ill patients in intensive care

The latest results from an expedition to Mount Everest that looked at the body's response to low oxygen levels suggest that drugs or procedures that promote the body's production of a chemical compound called nitric oxide (NO) could improve the recovery of critically ill patients in intensive care.

7 Oct 2011

Virginia Bioinformatics Institute releases upgraded ENISI software

Researchers with the Virginia Bioinformatics Institute at Virginia Tech have released an upgrade to the institute's ENteric Immunity SImulator (ENISI) software, which models immune responses to beneficial and harmful bacteria that enter the gastrointestinal tract of mice, pigs, and humans.

7 Oct 2011

Life Technologies, CHEO researcher partner to co-develop microbial detection tests

The Children's Hospital of Eastern Ontario (CHEO) Research Institute is pleased to announce that one of its principal investigators in infectious disease has signed a contract with Life Technologies, an internationally renowned biotech tools company headquartered in Carlsbad, California, to share information that will help to develop tests that uniquely amplify and detect the DNA coding for infectious diseases.

4 Oct 2011

DNA primer vaccine enhances immune response to H5N1 avian influenza vaccine

The immune response to an H5N1 avian influenza vaccine was greatly enhanced in healthy adults if they were first primed with a DNA vaccine expressing a gene for a key H5N1 protein, researchers say.

4 Oct 2011

Chad launches three-day polio vaccination campaign

Chad's President Idris Deby, alongside Bill Gates, co-chair of the Bill & Melinda Gates Foundation, on Friday launched a three-day polio vaccination campaign at the Friendship China-Chad hospital "as part of efforts to rid the central African nation of the infectious disease," AlertNet reports.

4 Oct 2011

Adaptimmune announces new board appointments as clinical programmes get underway

Adaptimmune, the T cell therapy company pioneering enhanced T cell receptor-driven T cells for the treatment of cancer and infectious disease, announces two new Board appointments with immediate effect. Dr Jonathan Knowles joins the Board as a non-executive director and Dr Helen Tayton-Martin, Adaptimmune’s Chief Operating Officer, becomes an executive director.

3 Oct 2011

GeoVax completes enrollment for HIV/AIDS vaccine Phase 2a clinical trial

GeoVax Labs, Inc., an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, announced today the completion of enrollment for a Phase 2a clinical trial testing its HIV/AIDS vaccine.

3 Oct 2011

Public health officials should determine community storage of anthrax-preventing antibiotics

As part of preparations for a possible large-scale anthrax attack, public health officials on the state and local levels should determine where and how anthrax-preventing antibiotics should be stored in their communities, says a new report from the Institute of Medicine.

1 Oct 2011

Multi-drug resistance in first-time TB patients shows 'substantial' transmission of MDR-TB, study says

Nearly half of patients diagnosed with multi-drug resistant tuberculosis (MDR-TB) at a Chinese hospital had not had the disease before, showing "'substantial' transmission of the deadly superbug," according to a study conducted by researchers from the Chinese Center for Disease Control and Prevention and published in the journal Emerging Infectious Diseases, Bloomberg reports.

1 Oct 2011

New analyses from Phase III studies of VICTRELIS to be presented at AASLD 2011

Merck, known as MSD outside of the United States and Canada, announced today that several new analyses from Phase III studies of VICTRELIS (boceprevir), the company's first-in-class, oral hepatitis C virus NS3/4A protease inhibitor will be presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.

1 Oct 2011

CMA welcomes Supreme Court ruling on Vancouver's supervised injection facility

The Canadian Medical Association (CMA) welcomed today the unanimous ruling by the Supreme Court of Canada allowing Vancouver's supervised drug injection facility, Insite, to continue to operate.

1 Oct 2011

Patients with chronic hepatitis C less likely to take medications over time

Patients being treated for chronic hepatitis C become less likely to take their medications over time, according to a new study from the Perelman School of Medicine at the University of Pennsylvania.

30 Sep 2011

Roads may play a major role in the spread or containment of antibiotic resistant bacteria

Antibiotic resistant E. coli was much more prevalent in villages situated along roads than in rural villages located away from roads, which suggests that roads play a major role in the spread or containment of antibiotic resistant bacteria, commonly called superbugs, a new study finds.

30 Sep 2011

G-Zero receives NIAID's Phase II Small Business Innovation Research Grant

G-Zero Therapeutics, an RTP company started in 2008 based on technologies from the University of North Carolina at Chapel Hill, has been awarded a $3 million Phase II Small Business Innovation Research Grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

30 Sep 2011

Oral tenofovir discontinued in HIV clinical trial

A large-scale clinical trial evaluating whether daily use of an oral tablet or vaginal gel containing antiretroviral drugs can prevent HIV infection in women is being modified because an interim review found that the study cannot show that one of the study products, oral tenofovir, marketed under the trade name Viread, is effective.

29 Sep 2011

Low-tech, inexpensive interventions for bedsores could benefit long-term care residents

Researchers at the University of Toronto have found that low-tech, inexpensive interventions for bedsores could improve health for long-term care residents and reduce health-care costs for the facilities that house them.

29 Sep 2011

VOICE HIV prevention trial to discontinue use of tenofovir tablets

VOICE, an HIV prevention trial evaluating two antiretroviral (ARV)-based approaches for preventing the sexual transmission of HIV in women - daily use of one of two different ARV tablets or of a vaginal gel - will be dropping one of the oral tablets from the study.

29 Sep 2011

USAID, NGO partners testing nutritional impact assessment tool

USAID is working with non-governmental organization partners to test a "nutritional impact assessment tool" that "'would be a way for organizations designing or reviewing agricultural programs to mitigate any risks or potential negative effects on nutrition -- in other words a "do no harm" approach,' said Michael Zeilinger, head of the nutrition division with USAID's office of health, infectious disease and nutrition," IRIN reports.

28 Sep 2011

Anthrax defenses need to be strengthened: Experts

It has been a decade since the anthrax attacks brought home the reality of bioterrorism and the nation now has a stockpile of some basic tools to fight back against a few of the threats that worry defense experts the most.

28 Sep 2011

'Urgent action' needed to prevent resistance to antiretroviral therapy

"The clear pattern of increasing antiretroviral resistance in lower-income settings must be considered in the context of the worldwide HIV-control agenda," especially because "the increasing rates of antiretroviral resistance in low-income settings represent a potential threat to the emerging treatment-as-prevention strategy," Evan Wood and Julio Montaner of the BC Centre for Excellence in HIV/AIDS write in a Lancet Infectious Diseases opinion piece.

28 Sep 2011